The Ministry of Health of the Russian Federation issued the Swiss Roche a registration certificate for the antitumor drug Lansumio (mosunetuzumab), intended to combat relapsed or refractory follicular lymphoma. The condition for treatment is that the patient undergoes at least two lines of systemic therapy.
In particular, Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody and a new class of fixed-duration cancer immunotherapy, according to a press release from Genentech, the manufacturer of the drug.
Patients in the study had an objective response rate (the percentage of patients with a partial or complete response to treatment) of 80%, with most patients maintaining response to the treatment for at least 18 months, according to the release. Patients also had a median duration of response (the length of time a tumor continues to respond to treatment without cancer growth or spread) of 22.8 months. Complete responses (disappearance of all signs of cancer in the body) to the treatment were observed in 60% of patients.
The most common side effect related to Lunsumio was cytokine release syndrome, which lasted for a median of three days. Of note, cytokine release syndrome is a condition that may occur after treatment with some immunotherapies when cytokines are rapidly released into the blood, resulting in fever, nausea, rash, headache, low blood pressure, rapid heartbeat and trouble breathing.
Other side effects included rash, fatigue, fever and headache, according to the release.
